OncoMatch/Clinical Trials/NCT05762900
Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients
Is NCT05762900 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for breast cancer.
This is a phase II study to investigate the feasibility of Ultra-hypofractionated radiotherapy with or without simultaneous integrated boost for low risk breast cancer patients who have received breast conservative surgery of mastectomy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Required: Stage YPT0-2N0-1, PT0-2N0-1
Stage ypT0-2N0-1 (if receive neoadjuvant therapy) or stage pT0-2N0-1 (if receive upfront surgery)
Demographics
Prior therapy
Cannot have received: radiation therapy
Lab requirements
Blood counts
hemoglobin ≥100g/l, leukocyte ≥2×109/l, neutrophil ≥1×109/l, platelet ≥80×109/l
Kidney function
creatinine 1.5 mg/dl or less
Liver function
alanine aminotransferase/aspartate aminotransferase ≤2.5×unl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05762900 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage YPT0-2N0-1 or PT0-2N0-1 is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages